New study IDs a fresh approach on fighting AML

Two molecules--Hif-1alpha and Hif-2alpha--work together to stop the formation of leukemic stem cells in acute myeloid leukemia, according to a new study from the University of Edinburgh. "Our discovery that Hif-1alpha and Hif-2alpha molecules act together to stop leukemia development is a major milestone in our efforts to combat leukemia," said Professor Kamil R Kranc, Cancer Research UK Senior Fellow at the MRC Centre for Regenerative Medicine. "We now intend to harness this knowledge to develop curative therapies that eliminate leukemic stem cells, which are the underlying cause of AML." Release

Suggested Articles

Astellas’ Xospata and Novartis’ Rydapt may help treat lung cancer that has grown resistant to EGFR inhibitors, researchers discovered.

Dutch scientists used stem cells from CF patients to demonstrate a technique that corrects a mutation in the gene CFTR without having to cut DNA.

A new map of the thymus gland could help researchers understand how T cells develop and inspire treatments for cancer and autoimmune disease.